Xueru Fan
Xiaoge Wang
Yang Chao1,2- 1Department of Gastroenterology, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou, China
- 2Department of Traditional Chinese Medicine, The First Clinical Medical College, Henan University of Traditional Chinese Medicine, Zhengzhou, China
- 3Department of Traditional Chinese Medicine, Henan University of Traditional Chinese Medicine, Zhengzhou, China
Inflammatory bowel disease (IBD), a chronic relapsing inflammatory disorder of the gastrointestinal tract, significantly increases the risk of progression to colorectal cancer (CRC). Emerging studies highlight the critical roles of gut microbial dysbiosis and sustained intestinal inflammation in driving this pathological transformation. Probiotics and prebiotics, as modulators of gut microbial ecology, have attracted considerable attention as potential interventions to restore microbial balance, regulate immune responses, and mitigate carcinogenic processes. In this review, we integrate the interplay mechanisms among inflammation, microbiota, and immunity in IBD-associated colorectal carcinogenesis (IBD-CRC), with a focus on the roles of probiotics and prebiotics in microbial remodeling, enhancement of epithelial barrier integrity, inhibition of inflammatory signaling, and activation of antitumor immunity. Furthermore, we discuss preclinical and clinical evidence supporting their efficacy in delaying or preventing IBD-CRC. The review also provides perspectives on future customized synbiotic strategies in microbiota-targeted therapy and cancer prevention.
1 Introduction
Inflammatory bowel disease (IBD), encompassing ulcerative colitis (UC) and Crohn’s disease (CD), is a chronic gastrointestinal disorder characterized by dysregulated immune responses and persistent inflammation. Patients with long-standing IBD face a substantially increased risk of developing colorectal cancer (CRC), especially in cases of extensive or poorly controlled disease (1). This progression exemplifies inflammation-driven carcinogenesis. Recent evidence underscores the critical role of the gut microbiota in maintaining mucosal immune homeostasis, preserving epithelial integrity, and influencing tumorigenesis. Dysbios, characterized by reduced commensal diversity and overgrowth of pathogenic bacteria, is a common feature in both IBD and CRC, contributing to barrier dysfunction and pro-inflammatory signaling (2). These interactions between inflammation, microbiota, and immunity collectively drive colorectal tumor development (3).
Probiotics, defined as viable beneficial microbes, and prebiotics, defined as selective substrates for commensal bacteria, represent emerging nutritional approaches for reshaping gut microbial ecology and function. A growing body of experimental and clinical research indicates that both probiotics and prebiotics can mitigate gut inflammation, enhance mucosal defense, and promote the production of bioactive metabolites, particularly short-chain fatty acids (SCFAs), which confer immunoregulatory and antitumor effects (4, 5).
This review summarizes current mechanistic insights into how probiotics and prebiotics influence the complex interplay among inflammation, microbiota, and immune responses in IBD-associated colorectal carcinogenesis (IBD-CRC). We highlight their roles in microbial modulation, immune regulation, and tumor suppression, providing novel perspectives for gut-targeted cancer-prevention strategies.
2 Microbial-immune-inflammatory interactions in IBD-CRC
The pathogenesis of IBD-CRC is caused by chronic inflammation, microbial dysbiosis, and impaired barrier function, all of which collectively contribute to a tumor-promoting microenvironment (Figure 1).
Figure 1. Mechanistic overview of microbiota-immune-inflammation interactions.
2.1 Chronic inflammation and epithelial damage
Persistent and recurrent inflammation of the intestinal mucosa is a defining feature of IBD. Chronic inflammatory stimuli promote cycles of epithelial injury and regeneration, increasing the risk of dysplasia and malignant transformation. Key pro-inflammatory cytokines, such as TNF-α, IL-6, and IL-1β, activate signaling pathways including NF-κB and STAT3, which promote epithelial cell proliferation, inhibit apoptosis, and establish a microenvironment conducive to tumor development (6, 7). Importantly, these inflammatory cascades further alter the gut microbial composition and impair immune tolerance, thereby establishing a vicious cycle that drives disease progression (8).
2.2 Dysbiosis and microbial metabolites
IBD and CRC are both characterized by gut microbial dysbiosis, including a reduction in beneficial commensals (e.g., Faecalibacterium prausnitzii) and an enrichment of pro-inflammatory or genotoxic species (e.g., Fusobacterium nucleatum, pks+ Escherichia coli). Such dysbiosis alters microbial metabolism, resulting in the production of harmful compounds such as secondary bile acids and reactive oxygen species (ROS), which contribute to DNA damage, mutagenesis, and initiation of tumorigenesis (9). Microbial dysbiosis also exacerbates mucosal inflammation and impairs immune homeostasis, thereby amplifying carcinogenic processes (10).
2.3 Barrier dysfunction and immune crosstalk
In IBD, compromised intestinal barrier integrity increases epithelial permeability, facilitating the translocation of microbial components such as lipopolysaccharide (LPS) into the lamina propria. This triggers chronic immune activation and recruits innate immune cells—macrophages and neutrophils—that secrete inflammatory cytokines and ROS, exacerbating mucosal injury and tumor risk (11, 12). Moreover, impaired tolerance to commensals disturbs the balance between regulatory T cells (Tregs) and pro-inflammatory Th17 cells, leading to a dysregulated immune microenvironment that paradoxically suppresses anti-tumor immunity while promoting tumor progression (13).
3 Mechanisms of probiotic and prebiotic therapeutics in IBD-CRC
The therapeutic effects of probiotics and prebiotics in IBD-CRC are primarily mediated through the reshaping of gut microbiota and functional metabolite production, suppression of inflammatory signaling pathways, restoration of intestinal barrier integrity, and modulation of host immune responses (Figure 2).
Figure 2. Experimental evidence pathway of probiotic/prebiotic intervention in IBD-CRC.
3.1 Reshaping gut microbiota and functional metabolite production
Gut microbiota composition and diversity are fundamental to intestinal homeostasis. In IBD-CRC, dysbiosis manifests as a loss of beneficial taxa such as Faecalibacterium prausnitzii, Akkermansia muciniphila, and Bifidobacterium spp., accompanied by an overgrowth of pro-inflammatory and genotoxic bacteria including Escherichia coli (particularly pks+ strains) and Fusobacterium nucleatum (14, 15). This microbial imbalance promotes mucosal inflammation, disrupts metabolic homeostasis, and facilitates tumor development.
Probiotics restore microbial balance by introducing beneficial strains that outcompete pathogens, modulate mucosal immunity, and regulate metabolic activity. For instance, Lactobacillus rhamnosus GG (LGG) increases microbial α-diversity and decreases Fusobacterium abundance in colitis models (16), while Bifidobacterium breve M-16 V modulates immune responses by suppressing Th2-type inflammation and inducing IL-10 production (17). Prebiotics such as inulin, fructooligosaccharides (FOS), and galactooligosaccharides (GOS) selectively stimulate SCFA-producing bacteria—particularly Faecalibacterium prausnitzii, Roseburia spp., and Eubacterium rectale—thereby enriching anti-inflammatory microbial communities (18–20). Synbiotic formulations, combining specific probiotics and compatible prebiotics, further enhance these effects. For example, Lactobacillus plantarum combined with inulin markedly increases butyrate-producing taxa, reduces colonic inflammation, and suppresses tumor formation in preclinical studies (21).
A key consequence of this microbial remodeling is the enhanced generation of bioactive metabolites, especially SCFAs such as acetate, propionate, and butyrate. SCFAs are generated via fermentation of dietary fibers and prebiotics by commensal bacteria including Faecalibacterium prausnitzii and Roseburia spp. (22, 23). Among them, butyrate serves as a central mediator connecting microbial restoration to mucosal protection. It fuels colonocytes, strengthens epithelial integrity, and suppresses inflammatory signaling through histone deacetylase (HDAC) inhibition and activation of G-protein-coupled receptors (GPR41, GPR109A) (24). Parallel studies indicate that acetate and propionate have broader systemic actions: acetate contributes to peripheral Treg expansion and influences host metabolic pathways via GPR43/FFAR2, while propionate affects bone-marrow hematopoiesis, altering myeloid cell generation and function, and consequently attenuating systemic inflammatory responses. These mechanisms may involve GPR41/FFAR3 signaling as well as epigenetic modulation. Collectively, SCFAs act complementarily to sustain mucosal tolerance and systemic metabolic homeostasis (25, 26). Moreover, probiotics and prebiotics influence the biosynthesis of other bioactive compounds such as tryptophan-derived indoles and bile acid metabolites, which act through aryl hydrocarbon receptor (AhR) to regulate immune responses and inhibit carcinogenesis (27, 28).
3.2 Suppressing inflammatory signaling pathways
Chronic activation of inflammatory signaling cascades, including nuclear factor-κB (NF-κB), signal transducer and activator of transcription3 (STAT3), and mitogen-activated protein kinases (MAPKs), links persistent mucosal inflammation to neoplastic transformation in IBD-CRC (29, 30). Probiotic and prebiotic interventions mitigate these inflammatory circuits through dual mechanisms—direct microbial actions and metabolite-mediated effects, particularly those involving SCFAs.
Probiotics such as Lactobacillus plantarum and LGG inhibit IκB phosphorylation, thereby preventing NF-κB nuclear translocation and reducing the expression of TNF-α and IL-1β in colitis models (31, 32). Likewise, Bifidobacterium infantis downregulates STAT3 phosphorylation, suppressing epithelial hyperplasia and inflammation. Meanwhile, SCFAs, particularly butyrate generated from the fermentation of prebiotics by Faecalibacterium prausnitzii, Roseburia spp., and Eubacterium rectale, function as HDAC inhibitors to attenuate NF-κB and STAT3 activation, resulting in reduced IL-6 and TNF-α production (33–35). Prebiotics such as inulin and FOS amplify this anti-inflammatory potential by enriching SCFA-producing taxa and sustaining metabolite availability (36).
3.3 Repairing intestinal barrier integrity
The intestinal epithelial barrier is essential for mucosal defense, preventing luminal antigens and pathogens from translocating across the gut wall. Barrier dysfunction represents a hallmark of IBD and promotes inflammation-driven tumorigenesis (37). Probiotic and prebiotic enhance epithelial integrity via microbial and metabolite-mediated pathways that regulate tight junction proteins, mucus secretion, and epithelial renewal.
Probiotics such as LGG and Bifidobacterium longum strengthen epithelial cohesion by upregulating tight junction components (ZO-1, claudin-1, occludin) and activating ERK and PKC pathways that promote epithelial survival (38, 39). Concurrently, the key metabolites of prebiotics, SCFAs, support barrier function by serving as the main energy source for colonocytes and by enhancing mucin synthesis through the activation of GPR43 and GPR109A (40). Butyrate, as the most biologically active SCFA, can also inhibit the expression of myosin light-chain kinase (MLCK), thereby preventing the disassembly of tight junctions and intercellular leakage (41). Synbiotics exhibit additive effects in this process. For example, a specific synbiotic composed of FOS and eight probiotic strains has been shown to reduce intestinal permeability and restore tight junction integrity in AOM/DSS-induced colitis-associated cancer (CAC) mouse models, significantly upregulating ZO-1 (and occludin) mRNA and protein expression (42). Collectively, these interactions form a mechanistic bridge linking microbial modulation to mucosal protection.
3.4 Modulating host immune responses
The immune system constitutes a critical interface connecting microbial perturbations to chronic inflammation and carcinogenesis in IBD-CRC (43). Probiotic and prebiotic interventions restore immune equilibrium by jointly reshaping the gut microbiota and driving the generation of immunoregulatory metabolites. Through both direct microbial actions and metabolite-mediated mechanisms, these interventions modulate innate and adaptive immune responses to maintain intestinal homeostasis (44).
Accumulating evidence indicates that Bifidobacterium infantis 35,624 exerts immunoregulatory activity by enhancing IL-10 production and promoting the expansion of Foxp3+ regulatory T cells, accompanied by a reduction in IFN-γ– and IL-17–producing effector T-cell subsets in preclinical models. These immune-modulating effects appear to involve the induction of tolerogenic dendritic cells, thereby contributing to the restoration of intestinal immune homeostasis (45). Prebiotics such as inulin and GOS selectively stimulate beneficial gut microbes, especially bifidobacteria, and can further promote the enrichment of SCFA-producing taxa, including Faecalibacterium prausnitzii and Roseburia spp., through cross-feeding networks, although such increases are context-dependen (46, 47). Butyrate, the prototypical colonic SCFA, serves as a primary energy source for colonocytes and promotes colonic regulatory T-cell differentiation via inhibition of histone deacetylases and enhancement of Foxp3 expression and function (48, 49).
Beyond SCFAs, other microbial metabolites participate in immune regulation. Tryptophan catabolites (e.g., indole-3-aldehyde and indole-3-propionic acid) activate the aryl hydrocarbon receptor (AhR), promoting IL-22 secretion by innate lymphoid cells (ILC3s) and enhancing mucosal defense and repair. Secondary bile acids such as lithocholic acid (LCA) and deoxycholic acid (DCA) signal through FXR and TGR5 to suppress pro-inflammatory macrophage activation (50).
4 Experimental evidence from preclinical models
IBD and CRC represent distinct but interconnected stages within a pathological continuum characterized by microbial dysbiosis, barrier disruption, and chronic inflammation. The progression from IBD to CRC highlights the essential involvement of gut microbiota–immune interactions in disease development. This continuum provides a rationale for investigating probiotic and prebiotic applications as a strategic approach to intercept disease evolution, an approach supported by preclinical studies demonstrating their efficacy in ameliorating intestinal inflammation, suppressing pro-carcinogenic signaling, restoring barrier function, and modulating anti-tumor immunity (Table 1).
Table 1. Representative studies on probiotics and butyrate in IBD and CRC models.
4.1 Anti-inflammatory effects of probiotics and prebiotics in IBD models
Numerous preclinical studies have demonstrated that probiotics and prebiotics possess therapeutic potential in reducing intestinal inflammation in IBD models. Commonly used animal models include dextran sulfate sodium (DSS)-induced colitis, trinitrobenzene sulfonic acid (TNBS)-induced colitis, and IL-10 knockout mice, all of which replicate critical features of human IBD pathophysiology.
Probiotic strains, including Lactobacillus rhamnosus GG, Bifidobacterium breve, and Akkermansia muciniphila, effectively lower the disease activity index (DAI), enhance tight junction protein expression (such as ZO-1 and occludin), and reduce pro-inflammatory cytokines such as TNF-α and IL-6. These benefits are linked to increased gut microbial diversity and mucus barrier repair. Prebiotics such as inulin, FOS, and resistant starch exert anti-inflammatory effects by boosting SCFA production, especially butyrate. Butyrate suppresses NF-κB activation and facilitates regulatory T-cells differentiation, thereby reducing mucosal inflammation (51, 52). Synbiotics, combining probiotics and prebiotics, provide synergistic advantages. For example, administration of Bifidobacterium longum with inulin reduced colitis severity and improved epithelial barrier integrity in Piglet models more effectively than either component alone (53). Collectively, these results highlight the promise of microbiota-focused therapies in reestablishing immune homeostasis, repairing barrier function, and reducing intestinal inflammation in IBD.
4.2 Anti-tumor effects of probiotics and prebiotics in CRC models
Preclinical studies using CRC models provided compelling evidence that probiotics and prebiotics can modulate the tumor microenvironment, inhibit carcinogenesis, and improve treatment outcomes. Commonly employed CRC models include azoxymethane/dextran sulfate sodium (AOM/DSS)-induced colitis-associated cancer (CAC), genetically modified APCMin/+ mice, and xenograft models.
Probiotic strains such as Lactobacillus casei, Bifidobacterium lactis, and Akkermansia muciniphila inhibit tumor development by lowering pro-inflammatory cytokines (IL-6 and IL-17), suppressing NF-κB and STAT3 signaling, and enhancing anti-tumor immune responses (54, 55). Notably, Akkermansia muciniphila restores mucosal barrier function and increase cytotoxic CD8+ T cell infiltration in AOM/DSS models. Prebiotics, through fermentation into SCFAs such as butyrate, exert epigenetic and immunoregulatory effects that inhibit tumors. Butyrate suppresses HDACs, enhances tumor suppressor genes (p21, Bax), and induces apoptosis in colorectal cancer cells (56). Synbiotic interventions demonstrate synergistic anti-cancer effects. For example, Bifidobacterium longum combined with inulin significantly reduced tumor number and volume in AOM/DSS mice, enhanced local IL-10 and IFN-γ expression, and restored microbiota composition (57). These findings underscore the potential of microbiota-directed interventions not only in inflammation control but also in preventing and suppressing of colorectal tumorigenesis.
Although animal studies provide strong supporting evidence, translating microbiota-based interventions to humans remains challenging due to interindividual variability and microbial diversity. Increasing attention has been directed toward synbiotic design and personalized intervention strategies.
5 Clinical trials and translational research
Clinical research has increasingly explored the therapeutic potential of probiotics, prebiotics, and synbiotics in IBD and CRC. Several clinical studies report beneficial effects, including reducing inflammation, promoting mucosal healing, preventing postoperative infections, and improving treatment tolerance—particularly in UC and perioperative CRC care (Table 2). However, despite these encouraging findings, translating microbiota-based interventions from experimental models into consistent clinical outcomes remains challenging. Considerable heterogeneity across trials reflects the complexity of host–microbe interactions. This underscores the need for more rigorous and stratified clinical evaluation.
Table 2. Clinical evidence for probiotics and synbiotics in IBD and CRC management.
In IBD, randomized controlled trials (RCTs) investigating the probiotic strain Escherichia coli Nissle 1917 have shown benefits in maintaining remission in UC and preventing pouchitis, demonstrating efficacy comparable to mesalamine in several studies (58, 59). However, other RCTs have reported no significant advantage over standard therapy or placebo. Notably, negative or inconclusive outcomes occur more frequently in CD, a condition characterized by deeper transmural inflammation, distinct dysbiosis patterns, and greater ecological instability than UC (60, 61). Overall, these results highlight the complexity of clinical responses in IBD, which can be attributed to multiple layers of heterogeneity. The first level is intrinsic disease subtype differences, as UC and CD differ fundamentally in their inflammatory profiles and microbial ecology. A second layer of variability arises from strain specificity; for instance, while Escherichia coli Nissle 1917 demonstrates clinical efficacy, other strains such as Lactobacillus rhamnosus GG have failed to maintain remission in CD (62), underscoring that probiotic effects are not generalizable across species or even within genera. Methodological heterogeneity further limits cross-trial interpretation. Many studies are constrained by small sample sizes, short intervention periods, non-standardized clinical endpoints, and wide variation in probiotic dosages ranging from 108 to 1011 CFU/day. Additionally, prebiotic interventions frequently emphasize microbiota or SCFA shifts rather than validated clinical outcomes, contributing to inconsistent interpretations (63, 64). Finally, host- and context-specific factors substantially modify therapeutic response. Baseline microbiota composition is a key determinant: individuals with low baseline butyrate production exhibit greater SCFA increases following prebiotic supplementation (65). Habitual dietary fiber intake also modulates fermentative capacity and shapes clinical benefit (66). Concomitant medications—including corticosteroids, biologics, immunomodulators, and antibiotics—further alter intestinal microbial ecology and may obscure or amplify treatment effects.
Clinical evidence in CRC remains relatively limited. Small perioperative studies suggest that probiotics may reduce postoperative infections, attenuate inflammatory responses, and mitigate chemotherapy-induced dysbiosis (67). Synbiotics have also demonstrated potential in reducing chemotherapy-related gastrointestinal adverse effects by maintaining microbial homeostasis (68). Importantly, the therapeutic context in established CRC differs markedly from that in IBD. Most CRC studies assess probiotics or synbiotics as adjuvant therapies—aimed at improving treatment tolerance, reducing gastrointestinal toxicities, and restoring microbiota balance during chemotherapy—rather than as cancer-preventive interventions. By contrast, in IBD, microbiota-directed strategies are primarily intended to prevent or delay malignant transformation by suppressing chronic inflammation, correcting dysbiosis, and reducing genotoxic microbial metabolites. These distinct therapeutic goals require different mechanistic considerations and study designs, underscoring the need for prospective trials specifically focused on the pre-carcinogenic stage of IBD-CRC.
Translational studies combining high-throughput microbiome sequencing with metabolomic profiling are increasingly revealing the basis of interindividual response heterogeneity. For example, a crossover human prebiotic trial showed that individual identity strongly determines SCFA responses, and baseline fecal SCFA levels (such as butyrate) inversely correlate with response magnitude (69). Moreover, in a metabolic syndrome cohort, baseline microbial community structure distinguished probiotic “responders” from “non-responders” (70). Additionally, in the context of immunotherapy, fecal and serum SCFAs have been proposed as predictive biomarkers of treatment efficacy (71, 72).
6 Future strategies and challenges in microbiota-based precision therapy
6.1 Synbiotic optimization: rational design of strain-substrate combinations
Synbiotics, combining probiotics and prebiotics, offer enhanced therapeutic potential by delivering beneficial microbes alongside their supportive substrates. Emerging studies show that specific strain-substrate pairs, such as Bifidobacterium longum and inulin, can synergistically increase SCFA production, restore epithelial barrier function, and suppress pro-inflammatory signaling. In colitis and colorectal cancer models, these combinations significantly reduce disease activity indices, inflammatory cytokine levels, and tumor burden compared to the use of probiotics or prebiotics alone (73, 74). Such synergy highlights the potential of rational synbiotic formulation as a more effective therapeutic strategy.
6.2 Personalization and host–microbe interactions
Interindividual variability—including microbial composition, mucosal immunity, IBD subtype, disease severity, and medication history—is a major determinant of clinical inconsistency. Certain probiotics benefit patients with identifiable microbial deficits but may exert limited effects in those with balanced microbiota (75). Multi-omics technologies enable the identification of functional microbial signatures and prediction of therapeutic responsiveness, allowing refined patient stratification and tailored synbiotic design (76, 77). Personalized strategies may include custom probiotics, targeted prebiotics, and AI-guided microbial reconstruction to maximize therapeutic efficacy while minimizing variability or adverse responses.
6.3 Translational barriers and regulatory challenges
Despite growing evidence for the biological relevance of microbiota-based interventions, several barriers hinder clinical translation. Response variability, driven by baseline microbiota, immune status, diet, genetics, and medication use, limits reproducibility across patient populations (78). The absence of standardized formulations, manufacturing practices, and dosing regimens further complicates evaluation. Many commercial products lack rigorous clinical validation, and their microbial viability varies widely (79). Mechanistic pathways linking microbiota modulation to host immunity and epithelial repair remain incompletely understood, underscoring the need for integrated metagenomic, metabolomic, and transcriptomic analyses (80). Additionally, live microbial therapeutics raise regulatory and ethical challenges regarding classification, safety assessment, and production standards. Well-designed clinical trials and validated biomarkers are urgently required.
6.4 Future perspectives: from AI to precision synbiotics
Looking ahead, the integration of AI, high-throughput sequencing, and machine learning will revolutionize microbiota-based interventions. AI can aid in predicting patient-specific responses, optimizing strain-substrate combinations, and identifying microbial signatures linked to treatment efficacy. Future directions include next-generation designer probiotics with defined immunomodulatory functions, custom prebiotics targeting microbial deficits, and AI-guided synbiotic platforms for personalized therapy. Distinguishing the preventive role of microbiota modulation in IBD-CRC from its adjunctive function in established CRC treatment will be essential for guiding future clinical trial design and precision therapy development. These innovations will facilitate the transition from empirical usage to precision microbiota medicine.
7 Conclusion
Probiotics, prebiotics, and synbiotics constitute a promising class of microbiota-targeted therapies capable of modulating gut microbial composition, attenuating inflammation, and disrupting colorectal carcinogenesis. This review highlights their mechanisms within the intricate interplay among inflammation, microbial communities, and host immune responses, particularly in the context of IBD-CRC. These interventions enhance microbial diversity, reinforcing epithelial barrier integrity, promote the production of beneficial metabolites such as SCFAs, and regulate immune homeostasis, thereby exerting multifaceted preventive and therapeutic effects across disease stages. Robust preclinical evidence supports their anti-inflammatory and antineoplastic properties, while emerging clinical data indicate adjunctive benefits in disease management. Despite challenges including individual heterogeneity and the need for standardized protocols, advances in multi-omics and precision medicine foster the integration of microbiome-based strategies into personalized therapeutic frameworks. Incorporating microbial-targeted approaches into dietary or nutrition-based interventions may provide new opportunities for colorectal cancer prevention. Future investigations should prioritize rigorously designed large-scale clinical trials, personalized synbiotic formulations, and identification of microbiome-derived biomarkers to optimize patient stratification and therapeutic efficacy. Collectively, microbiota-directed therapies offer a novel and integrative avenue for improving outcomes in IBD and CRC, with the potential to transform prevention, treatment, and long-term disease management.
Author contributions
XF: Writing – original draft, Writing – review & editing. XW: Conceptualization, Methodology, Writing – review & editing. YC: Data curation, Formal analysis, Writing – review & editing. EX: Conceptualization, Methodology, Writing – review & editing.
Funding
The author(s) declared that financial support was received for this work and/or its publication. This study was supported by the National Natural Science Foundation of China.
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that Generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Axelrad, JE, Lichtiger, S, and Yajnik, V. Inflammatory bowel disease and cancer: the role of inflammation, immunosuppression, and cancer treatment. World J Gastroenterol. 22:4794. doi: 10.3748/wjg.v22.i20.4794,
2. Wong, SH, and Yu, J. Gut microbiota in colorectal cancer: mechanisms of action and clinical applications. Nat Rev Gastroenterol Hepatol. (2019) 16:690–704. doi: 10.1038/s41575-019-0209-8,
4. Zhou, T, Wu, J, Khan, A, Hu, T, Wang, Y, Salama, E-S, et al. A probiotic Limosilactobacillus fermentum GR-3 mitigates colitis-associated tumorigenesis in mice via modulating gut microbiome. NPJ Sci Food. (2024) 8. doi: 10.1038/s41538-024-00307-5
5. Rafter, J, Bennett, M, Caderni, G, Clune, Y, Hughes, R, Karlsson, PC, et al. Dietary synbiotics reduce cancer risk factors in polypectomized and colon cancer patients. Elsevier BV. 85:488–96. doi: 10.1093/ajcn/85.2.488
6. Neurath, MF. Strategies for targeting cytokines in inflammatory bowel disease. Nat Rev Immunol. (2024) 24:559–76. doi: 10.1038/s41577-024-01008-6
7. Greten, FR, and Grivennikov, SI. Inflammation and Cancer: triggers, mechanisms, and consequences. Immunity. (2019) 51:27–41. doi: 10.1016/j.immuni.2019.06.025,
8. Tilg, H, Adolph, TE, Gerner, RR, and Moschen, AR. The intestinal microbiota in colorectal Cancer. Cancer Cell. (2018) 33:954–64. doi: 10.1016/j.ccell.2018.03.004,
9. Yamada, T. Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer. BIO Web Conf. 41:01001. doi: 10.1051/bioconf/20214101001
10. Arthur, JC, Perez-Chanona, E, Mühlbauer, M, Tomkovich, S, Uronis, JM, Fan, T-J, et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science. (2012) 338:120–3. doi: 10.1126/science.1224820,
11. Allaire, JM, Crowley, SM, Law, HT, Chang, S-Y, Ko, H-J, and Vallance, BA. The intestinal epithelium: central coordinator of mucosal immunity. Trends Immunol. 40:174. doi: 10.1016/j.it.2018.12.008
12. Lopetuso, LR, Salvo, CD, Pastorelli, L, Rana, N, Senkfor, HN, Petito, V, et al. IL-33 promotes recovery from acute colitis by inducing miR-320 to stimulate epithelial restitution and repair. Proc Natl Acad Sci USA. (2018) 115. doi: 10.1073/pnas.1803613115
13. Omenetti, S, and Pizarro, TT. The treg/Th17 axis: a dynamic balance regulated by the gut microbiome. Front Media SA. (2015) 6. doi: 10.3389/fimmu.2015.00639
14. Pandey, H, Jain, D, Tang, DWT, Wong, SH, and Lal, D. Gut microbiota in pathophysiology, diagnosis, and therapeutics of inflammatory bowel disease. Intest Res. (2024) 22:15–43. doi: 10.5217/ir.2023.00080,
15. Sadeghi, M, Mestivier, D, and Sobhani, I. Contribution of Pks+ Escherichia Coli (E. coli) to colon carcinogenesis. Microorganisms. (2024) 12:1111. doi: 10.3390/microorganisms12061111,
16. Nakatsu, G, Li, X, Zhou, H, Sheng, J, Wong, SH, Wu, WKK, et al. Gut mucosal microbiome across stages of colorectal carcinogenesis. Nat Commun. (2015) 6. doi: 10.1038/ncomms9727,
17. Inoue, Y, Iwabuchi, N, Xiao, J, Yaeshima, T, and Iwatsuki, K. Suppressive effects of Bifidobacterium breve strain M-16V on T-helper type 2 immune responses in a murine model. Biol Pharm Bull. 32:760–3. doi: 10.1248/bpb.32.760,
18. Alamdary, SZ, Halimi, S, Rezaei, A, and Afifirad, R. Association between probiotics and modulation of gut microbial community composition in colorectal Cancer animal models: a systematic review (2010–2021). Wiley. (2023) 2023:1–21. doi: 10.1155/2023/3571184,
19. Guo, J, Li, L, Cai, Y, and Kang, Y. The development of probiotics and prebiotics therapy to ulcerative colitis: a therapy that has gained considerable momentum. Cell Commun Signal. (2024) 22. doi: 10.1186/s12964-024-01611-z,
20. Fagundes, RR, Bourgonje, AR, Saeed, A, Vila, AV, Plomp, N, Blokzijl, T, et al. Inulin-grown Faecalibacterium Prausnitzii cross-feeds fructose to the human intestinal epithelium. Gut Microbes. 13. doi: 10.1080/19490976.2021.1993582,
21. Strojný, L, Bomba, A, Hijová, E, Chmelárová, A, Mojžišová, G, Bertková, I, et al. Effects of a probiotic in combination with prebiotics on intestinal lactobacilli and coliforms and activities of bacterial enzymes in 1,2-dimethylhydrazine exposed rats. Czeh J Anim Sci. (2011) 56:99–106. doi: 10.17221/56/2010-cjas
22. Koh, A, Vadder, FD, Kovatcheva-Datchary, P, and Bäckhed, F. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell. 165:1332–45. doi: 10.1016/j.cell.2016.05.041,
23. Louis, P, Hold, GL, and Flint, HJ. The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol. (2014) 12:661–72. doi: 10.1038/nrmicro3344
24. Gasaly, N, Hermoso, MA, and Gotteland, M. Butyrate and the fine-tuning of colonic homeostasis: implication for inflammatory bowel diseases. Int J Mol Sci. (2021) 22:3061. doi: 10.3390/ijms22063061,
25. Trompette, A, Gollwitzer, ES, Yadava, K, Sichelstiel, AK, Sprenger, N, Ngom-Bru, C, et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat Med. (2014) 20:159–66. doi: 10.1038/nm.3444,
26. Smith, PM, Howitt, MR, Panikov, N, Michaud, M, Gallini, CA, Bohlooly-Y, M, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science. (2013) 341:569–73. doi: 10.1126/science.1241165,
27. Wyatt, M, and Greathouse, KL. Targeting dietary and microbial tryptophan-indole metabolism as therapeutic approaches to colon cancer. Nutrients. (2021) 13:1189. doi: 10.3390/nu13041189,
28. Vaaben, TH, Lützhøft, DO, Koulouktsis, A, Dawoodi, IM, Stavnsbjerg, C, Kvich, L, et al. Modulating tumor immunity using advanced microbiome therapeutics producing an indole metabolite. EMBO Rep. (2025) 26:1688–708. doi: 10.1038/s44319-025-00386-9,
29. Fan, Y, Mao, R, and Yang, J. NF-κB and STAT3 signaling pathways collaboratively link inflammation to cancer. Protein Cell. 4:176–85. doi: 10.1007/s13238-013-2084-3,
30. Shahgoli, VK, Noorolyai, S, Youshanlui, MA, Saeidi, H, Nasiri, H, Mansoori, B, et al. Inflammatory bowel disease, colitis, and cancer: unmasking the chronic inflammation link. Int J Color Dis. (2024) 39. doi: 10.1007/s00384-024-04748-y,
31. Li, Y, Yang, S, Lun, J, Gao, J, Gao, X, Gong, Z, et al. Inhibitory effects of the Lactobacillus rhamnosus GG effector protein HM0539 on inflammatory response through the TLR4/MyD88/NF-кB axis. Front Immunol. (2020) 11. doi: 10.3389/fimmu.2020.551449,
32. Chon, H, Choi, B, Jeong, G, Lee, E, and Lee, S. Suppression of proinflammatory cytokine production by specific metabolites of Lactobacillus Plantarum 10hk2 via inhibiting NF-κB and P38 MAPK expressions. Comp Immunol Microbiol Infect Dis. 33:e41–9. doi: 10.1016/j.cimid.2009.11.002,
33. Zhou, L, Zhang, M, Wang, Y, Dorfman, RG, Liu, H, Yu, T, et al. Faecalibacterium prausnitzii produces butyrate to maintain Th17/Treg balance and to ameliorate colorectal colitis by inhibiting histone deacetylase 1. Inflamm Bowel Dis. (2018) 24:1926–40. doi: 10.1093/ibd/izy182,
34. Lu, H, Xu, X, Fu, D, Gu, Y, Fan, R, Yi, H, et al. Butyrate-producing Eubacterium rectale suppresses lymphomagenesis by alleviating the TNF-induced TLR4/MyD88/NF-κB axis. Cell Host Microbe. 30:1139–1150.e7. doi: 10.1016/j.chom.2022.07.003
35. Luo, W, Shen, Z, Deng, M, Li, X, Tan, B, Xiao, M, et al. Roseburiaintestinalis supernatant ameliorates colitis induced in mice by regulating the immune response. Mol Med Rep. (2019). doi: 10.3892/mmr.2019.10327
36. Chandrarathna, HPSU, Liyanage, TD, Edirisinghe, SL, Dananjaya, SHS, Thulshan, EHT, Nikapitiya, C, et al. Marine microalgae, Spirulina maxima-derived modified pectin and modified pectin nanoparticles modulate the gut microbiota and trigger immune responses in mice. Mar Drugs. (2020) 18:175. doi: 10.3390/md18030175,
37. Turner, JR. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol. 9:799–809. doi: 10.1038/nri2653,
38. Tong, L, Zhang, X, Hao, H, Liu, Q, Zhou, Z, Liang, X, et al. Lactobacillus rhamnosus GG derived extracellular vesicles modulate gut microbiota and attenuate inflammatory in DSS-induced colitis mice. Nutrients. (2021) 13:3319. doi: 10.3390/nu13103319,
39. Wang, H, Sun, Y, Ma, X, Yang, T, and Wang, F. The Lactobacillus plantarum P-8 probiotic microcapsule prevents DSS-induced colitis through improving intestinal integrity and reducing colonic inflammation in mice. MDPI AG. (2024) 16:1055. doi: 10.3390/nu16071055,
40. Zhang, ZJ, Pedicord, VA, Peng, T, and Hang, HC. Site-specific acylation of a bacterial virulence regulator attenuates infection. Nat Chem Biol. (2019) 16:95–103. doi: 10.1038/s41589-019-0392-5,
41. Liu, L, Chen, T, Xie, Z, Zhang, Y, He, C, and Huang, Y. Butyric acid alleviates LPS-induced intestinal mucosal barrier damage by inhibiting the RhoA/ROCK2/MLCK signaling pathway in Caco2 cells. PLoS One. (2024) 19:e0316362. doi: 10.1371/journal.pone.0316362,
42. Wu, H, Wu, Z, Qiu, Y, Zhao, F, Liao, M, Zhong, Z, et al. Supplementing a specific synbiotic suppressed the incidence of AOM/DSS-induced colorectal cancer in mice. iScience. 26:106979. doi: 10.1016/j.isci.2023.106979,
43. Neurath, MF. Targeting immune cell circuits and trafficking in inflammatory bowel disease. Nat Immunol. (2019) 20:970–9. doi: 10.1038/s41590-019-0415-0,
44. Prescott, HC, Dickson, RP, Rogers, MAM, Langa, KM, and Iwashyna, TJ. Hospitalization type and subsequent severe sepsis. Am J Respir Crit Care Med. (2015) 192:581–8. doi: 10.1164/rccm.201503-0483oc,
45. Konieczna, P, Ferstl, R, Ziegler, M, Frei, R, Nehrbass, D, Lauener, RP, et al. Immunomodulation by Bifidobacterium infantis 35624 in the murine lamina propria requires retinoic acid-dependent and independent mechanisms. PLoS One. (2013) 8:e62617. doi: 10.1371/journal.pone.0062617,
46. Vulevic, J, Juric, A, Walton, GE, Claus, SP, Tzortzis, G, Toward, RE, et al. Influence of galacto-oligosaccharide mixture (B-GOS) on gut microbiota, immune parameters and metabonomics in elderly persons. Br J Nutr. (2015) 114:586–95. doi: 10.1017/s0007114515001889,
47. Ramirez-Farias, C, Slezak, K, Fuller, Z, Duncan, A, Holtrop, G, and Louis, P. Effect of inulin on the human gut microbiota: stimulation of Bifidobacterium Adolescentis and Faecalibacterium Prausnitzii. Br J Nutr. (2008) 101:541–50. doi: 10.1017/s0007114508019880
48. Arpaia, N, Campbell, C, Fan, X, Dikiy, S, van der Veeken, J, deRoos, P, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature. (2013) 504:451–5. doi: 10.1038/nature12726,
49. Furusawa, Y, Obata, Y, Fukuda, S, Endo, TA, Nakato, G, Takahashi, D, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature. (2013) 504:446–50. doi: 10.1038/nature12721,
50. Agus, A, Clément, K, and Sokol, H. Gut microbiota-derived metabolites as central regulators in metabolic disorders. Gut. (2020) 70:1174–82. doi: 10.1136/gutjnl-2020-323071,
51. Chen, G, Ran, X, Li, B, Li, Y, He, D, Huang, B, et al. Sodium butyrate inhibits inflammation and maintains epithelium barrier integrity in a TNBS-induced inflammatory bowel disease mice model. EBioMedicine. (2018) 30:317–25. doi: 10.1016/j.ebiom.2018.03.030,
52. Zhang, M, Zhou, Q, Dorfman, RG, Huang, X, Fan, T, Zhang, H, et al. Butyrate inhibits interleukin-17 and generates Tregs to ameliorate colorectal colitis in rats. BMC Gastroenterol. (2016) 16. doi: 10.1186/s12876-016-0500-x,
53. Rodríguez-Sorrento, A, Castillejos, L, López-Colom, P, Cifuentes-Orjuela, G, Moreno-Muñoz, JA, and Martín-Orúe, SM. Assessment of the effects of the synbiotic combination of Bifidobacterium longum subsp. infantis CECT 7210 and oligofructose-enriched inulin against digestive bacterial infections in a piglet model. Front Microbiol. (2022) 13. doi: 10.3389/fmicb.2022.831737,
54. Fan, L, Xu, C, Ge, Q, Lin, Y, Wong, CC, Qi, Y, et al. A. Muciniphila suppresses colorectal tumorigenesis by inducing TLR2/NLRP3-mediated M1-like TAMs. Cancer Immunol Res. (2021) 9:1111–24. doi: 10.1158/2326-6066.cir-20-1019
55. Jacouton, E, Chain, F, Sokol, H, Langella, P, and Bermúdez-Humarán, LG. Probiotic strain Lactobacillus casei BL23 prevents colitis-associated colorectal cancer. Front Immunol. (2017) 8. doi: 10.3389/fimmu.2017.01553,
56. Wang, L, Shannar, AAF, Wu, R, Chou, P, Sarwar, MS, Kuo, H, et al. Butyrate drives metabolic rewiring and epigenetic reprogramming in human colon cancer cells. Mol Nutr Food Res. (2022) 66. doi: 10.1002/mnfr.202200028,
57. Marchesi, JR, Adams, DH, Fava, F, Hermes, GDA, Hirschfield, GM, Hold, G, et al. The gut microbiota and host health: a new clinical frontier. BMJ. (2015) 65:330–9. doi: 10.1136/gutjnl-2015-309990,
58. Ikegami, S, Nakamura, M, Honda, T, Yamamura, T, Maeda, K, Sawada, T, et al. Efficacy of 1-kestose supplementation in patients with mild to moderate ulcerative colitis: a randomised, double-blind, placebo-controlled pilot study. Aliment Pharmacol Ther. (2023) 57:1249–57. doi: 10.1111/apt.17387,
59. Losurdo, G, Iannone, A, Contaldo, A, Ierardi, E, Leo, AD, and Principi, M. Escherichia coli Nissle 1917 in ulcerative colitis treatment: systematic review and meta-analysis. J Gastrointest Liver Dis. (2015) 24:499–505. doi: 10.15403/jgld.2014.1121.244.ecn,
60. Azevedo, KP, Catulio, MZ d J, Souza, RGM, and Stringhini, MLF. Probiotics in Crohn’s disease remission: a systematic review. Soc Latinoam Nutr. (2022) 72:50–9. doi: 10.37527/2022.72.1.006
61. Derwa, Y, Gracie, DJ, Hamlin, PJ, and Ford, AC. Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease. Aliment Pharmacol Ther. (2017) 46:389–400. doi: 10.1111/apt.14203,
62. Rolfe, VE, Fortun, PJ, Hawkey, CJ, and Bath-Hextall, FJ. Probiotics for maintenance of remission in Crohn’s disease. Wiley. (2006). doi: 10.1002/14651858.cd004826.pub2
63. Casellas, F, Borruel, N, Torrejón, A, Varela, E, Antolin, M, Guarner, F, et al. Oral oligofructose-enriched inulin supplementation in acute ulcerative colitis is well tolerated and associated with lowered faecal calprotectin. Aliment Pharmacol Ther. (2007) 25:1061–7. doi: 10.1111/j.1365-2036.2007.03288.x,
64. Lindsay, JO. Clinical, microbiological, and immunological effects of Fructo-oligosaccharide in patients with Crohn’s disease. BMJ. (2006) 55:348–55. doi: 10.1136/gut.2005.074971,
65. Korem, T, Zeevi, D, Zmora, N, Weissbrod, O, Bar, N, Lotan-Pompan, M, et al. Bread affects clinical parameters and induces gut microbiome-associated personal glycemic responses. Cell Metab. 25:1243–1253.e5. doi: 10.1016/j.cmet.2017.05.002
66. Healey, G, Murphy, R, Butts, C, Brough, L, Whelan, K, and Coad, J. Habitual dietary fibre intake influences gut microbiota response to an inulin-type fructan prebiotic: a randomised, double-blind, placebo-controlled, cross-over, human intervention study. Br J Nutr. (2018) 119:176–89. doi: 10.1017/s0007114517003440,
67. Liu, Z, Qin, H, Yang, Z, Xia, Y, Liu, W, Yang, J, et al. Randomised clinical trial: the effects of perioperative probiotic treatment on barrier function and post-operative infectious complications in colorectal cancer surgery – a double-blind study. Aliment Pharmacol Ther. (2010) 33:50–63. doi: 10.1111/j.1365-2036.2010.04492.x
68. Singh, NK, Beckett, JM, Kalpurath, K, Ishaq, M, Ahmad, T, and Eri, RD. Synbiotics as supplemental therapy for the alleviation of chemotherapy-associated symptoms in patients with solid tumours. Nutrients. (2023) 15:1759. doi: 10.3390/nu15071759,
69. Holmes, ZC, Villa, MM, Durand, HK, Jiang, S, Dallow, EP, Petrone, BL, et al. Microbiota responses to different prebiotics are conserved within individuals and associated with habitual fiber intake. Microbiome. (2022) 10. doi: 10.1186/s40168-022-01307-x,
70. Wastyk, HC, Perelman, D, Topf, M, Fragiadakis, GK, Robinson, JL, Sonnenburg, JL, et al. Randomized controlled trial demonstrates response to a probiotic intervention for metabolic syndrome that may correspond to diet. Gut Microbes. (2023) 15. doi: 10.1080/19490976.2023.2178794,
71. Lu, S, Wang, C, Ma, J, and Wang, Y. Metabolic mediators: microbial-derived metabolites as key regulators of anti-tumor immunity, immunotherapy, and chemotherapy. Front Immunol. (2024) 15. doi: 10.3389/fimmu.2024.1456030,
72. Malczewski, AB, Navarro, S, Coward, JI, and Ketheesan, N. Microbiome-derived metabolome as a potential predictor of response to cancer immunotherapy. BMJ. 8:e001383. doi: 10.1136/jitc-2020-001383,
73. Liu, H, Bian, Z, Zhang, Q, Xiao, Z, Cao, Y, Sun, X, et al. Sodium butyrate inhibits colitis-associated colorectal cancer through preventing the gut microbiota dysbiosis and reducing the expression of NLRP3 and IL-1β. J Funct Foods. 87:104862. doi: 10.1016/j.jff.2021.104862
74. Yang, Y, Qiao, Y, Liu, G, Chen, W, Zhang, T, Liu, J, et al. A novel synbiotic protects against DSS-induced colitis in mice via anti-inflammatory and microbiota-balancing properties. Probiotics Antimicrob Proteins. (2024) 17. doi: 10.1007/s12602-024-10393-2,
75. Zhao, F, Bai, X, Zhang, J, Kwok, L-Y, Shen, L, Jin, H, et al. Gut Bifidobacterium responses to probiotic LactobacillusCasei Zhang administration vary between subjects from different geographic regions. Appl Microbiol Biotechnol. (2022) 106:2665–75. doi: 10.1007/s00253-022-11868-4,
76. Lee, JWJ, Plichta, D, Hogstrom, L, Borren, NZ, Lau, H, Gregory, SM, et al. Multi-omics reveal microbial determinants impacting responses to biologic therapies in inflammatory bowel disease. Cell Host Microbe. 29:1294–1304.e4. doi: 10.1016/j.chom.2021.06.019,
77. O’Toole, PW, Marchesi, JR, and Hill, C. Next-generation probiotics: the spectrum from probiotics to live biotherapeutics. Nat Microbiol. (2017) 2. doi: 10.1038/nmicrobiol.2017.57,
78. Healey, GR, Murphy, R, Brough, L, Butts, CA, and Coad, J. Interindividual variability in gut microbiota and host response to dietary interventions. Nutr Rev. (2017) 75:1059–80. doi: 10.1093/nutrit/nux062,
79. Kolaček, S, Hojsak, I, Canani, RB, Guarino, A, Indrio, F, Orel, R, et al. Commercial probiotic products. J Pediatr Gastroenterol Nutr. 65:117–24. doi: 10.1097/mpg.0000000000001603,
80. Lacroix, V, Cassard, A, Mas, E, and Barreau, F. Multi-omics analysis of gut microbiota in inflammatory bowel diseases: what benefits for diagnostic, prognostic and therapeutic tools? Int J Mol Sci. (2021) 22:11255. doi: 10.3390/ijms222011255,
Keywords: inflammatory bowel disease, colorectal cancer, probiotics, prebiotics, synbiotics
Citation: Fan X, Wang X, Chao Y and Xu E (2026) Probiotic and prebiotic mechanisms in IBD-associated colorectal carcinogenesis: recent advances. Front. Nutr. 12:1693875. doi: 10.3389/fnut.2025.1693875
Edited by:
Christophe Lacroix, ETH Zürich, SwitzerlandReviewed by:
Apurva Jadhav, Bharati Vidyapeeth Deemed University, IndiaRoghayeh Afifirad, Tehran University of Medical Sciences, Iran
Copyright © 2026 Fan, Wang, Chao and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Xiaoge Wang, d2FuZ3hpYW9nZTIwMDdAMTYzLmNvbQ==; Erping Xu, eHVlcnBpbmcxOTYyQDE2My5jb20=